BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15944254)

  • 1. A defective viral superantigen-presenting phenotype in HLA-DR transfectants is corrected by CIITA.
    Azar GA; Sékaly RP; Thibodeau J
    J Immunol; 2005 Jun; 174(12):7548-57. PubMed ID: 15944254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of viral superantigen-class II MHC interactions at the cell surface.
    Reilly M; Mix D; Winslow GM
    Mol Immunol; 2000 Nov; 37(16):987-93. PubMed ID: 11395137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of mouse mammary tumor virus superantigen with MHC class II during biosynthesis.
    Hsu PN; Wolf Bryant P; Sutkowski N; McLellan B; Ploegh HL; Huber BT
    J Immunol; 2001 Mar; 166(5):3309-14. PubMed ID: 11207286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
    Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
    J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intercellular transfer of a soluble viral superantigen.
    Reilly M; Mix D; Reilly AA; Ye XY; Winslow GM
    J Virol; 2000 Sep; 74(18):8262-7. PubMed ID: 10954523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMTV superantigens coerce an unconventional topology between the TCR and MHC class II.
    Fortin JS; Genève L; Gauthier C; Shoukry NH; Azar GA; Younes S; Yassine-Diab B; Sékaly RP; Fremont DH; Thibodeau J
    J Immunol; 2014 Feb; 192(4):1896-906. PubMed ID: 24453254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polarized transport of MHC class II molecules in Madin-Darby canine kidney cells is directed by a leucine-based signal in the cytoplasmic tail of the beta-chain.
    Simonsen A; Pedersen KW; Nordeng TW; von der Lippe A; Stang E; Long EO; Bakke O
    J Immunol; 1999 Sep; 163(5):2540-8. PubMed ID: 10452991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paracrine transfer of mouse mammary tumor virus superantigen.
    Delcourt M; Thibodeau J; Denis F; Sekaly RP
    J Exp Med; 1997 Feb; 185(3):471-80. PubMed ID: 9053447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel antigen-processing-defective phenotype in major histocompatibility complex class II-positive CIITA transfectants is corrected by interferon-gamma.
    Siegrist CA; Martinez-Soria E; Kern I; Mach B
    J Exp Med; 1995 Dec; 182(6):1793-9. PubMed ID: 7500024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
    Muczynski KA; Anderson SK; Pious D
    J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides.
    Muntasell A; Carrascal M; Serradell L; Veelen Pv Pv; Verreck F; Koning F; Raposo G; Abián J; Jaraquemada D
    J Immunol; 2002 Nov; 169(9):5052-60. PubMed ID: 12391221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse repertoire of the MHC class II-peptide complexes is required for presentation of viral superantigens.
    Golovkina T; Agafonova Y; Kazansky D; Chervonsky A
    J Immunol; 2001 Feb; 166(4):2244-50. PubMed ID: 11160278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines.
    Weenink S; Averdunk H; Boston T; Boswarva V; Guery JC; Adorini L; Mellins E; McCluskey J; Gautam AM
    Int Immunol; 1997 Jun; 9(6):889-96. PubMed ID: 9199972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.
    Stüve O; Youssef S; Slavin AJ; King CL; Patarroyo JC; Hirschberg DL; Brickey WJ; Soos JM; Piskurich JF; Chapman HA; Zamvil SS
    J Immunol; 2002 Dec; 169(12):6720-32. PubMed ID: 12471103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density.
    Romieu-Mourez R; François M; Boivin MN; Stagg J; Galipeau J
    J Immunol; 2007 Aug; 179(3):1549-58. PubMed ID: 17641021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolytic processing activates a viral superantigen.
    Mix D; Winslow GM
    J Exp Med; 1996 Oct; 184(4):1549-54. PubMed ID: 8879228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of class II expression in monocytic cells after HIV-1 infection.
    Rakoff-Nahoum S; Chen H; Kraus T; George I; Oei E; Tyorkin M; Salik E; Beuria P; Sperber K
    J Immunol; 2001 Aug; 167(4):2331-42. PubMed ID: 11490022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
    Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
    Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical chaperones enhance superantigen and conventional antigen presentation by HLA-DM-deficient as well as HLA-DM-sufficient antigen-presenting cells and enhance IgG2a production in vivo.
    Ghumman B; Bertram EM; Watts TH
    J Immunol; 1998 Oct; 161(7):3262-70. PubMed ID: 9759841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
    Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
    Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.